COMPARISON OF THE EFFICACY, SAFETY AND COMPLIANCE OF KETOGENIC DIET WITH MODIFIED ATKINS DIET AND LOW GLYCEMIC INDEX TREATMENT IN CHILDREN WITH DRUG-RESISTANT EPILEPSY

Liwia Prorok; Aleksandra Potempa; Mateusz  Żyła; Zofia Parol; Aleksandra Ustaszewska; Aleksandra  Oszczypała; Michał Petkow; Katarzyna Lipska; Monika Szyszkowska; Zuzanna Strojek

doi:10.31435/ijitss.2(50).2026.5781

Authors

Liwia Prorok Medical University of Warsaw, Warsaw, Poland https://orcid.org/0009-0008-3762-514X
Aleksandra Potempa Medical University of Warsaw, Warsaw, Poland https://orcid.org/0009-0004-2698-4957
Mateusz Żyła Medical University of Warsaw, Warsaw, Poland https://orcid.org/0009-0003-9005-620X
Zofia Parol Medical University of Warsaw, Warsaw, Poland https://orcid.org/0009-0007-0885-2637
Aleksandra Ustaszewska Medical University of Warsaw, Warsaw, Poland https://orcid.org/0009-0001-5651-5906
Aleksandra Oszczypała Medical University of Warsaw, Warsaw, Poland https://orcid.org/0009-0006-5809-3934
Michał Petkow Medical University of Warsaw, Warsaw, Poland https://orcid.org/0009-0008-3398-9069
Katarzyna Lipska Medical University of Warsaw, Warsaw, Poland https://orcid.org/0009-0003-5670-7726
Monika Szyszkowska Medical University of Warsaw, Warsaw, Poland https://orcid.org/0009-0006-5367-0026
Zuzanna Strojek Medical University of Warsaw, Warsaw, Poland https://orcid.org/0009-0005-8857-5670

DOI:

https://doi.org/10.31435/ijitss.2(50).2026.5781

Keywords:

Pediatric Drug-Resistant Epilepsy, Ketogenic Diet, Modified Atkins Diet, Low Glycemic Index Treatment, Metabolic Therapy

Abstract

Metabolic dietary therapies serve as a multidimensional intervention for the estimated 30% of pediatric patients with epilepsy who remain refractory to standard antiseizure medications. This review evaluates the clinical utility of the classical ketogenic diet (cKD), modified Atkins diet (MAD), and low glycemic index treatment (LGIT), each utilizing a metabolic shift toward ketogenesis to modulate neuronal excitability and neuroinflammation. While the cKD remains the gold standard for achieving high-level seizure reduction and complete seizure freedom, MAD and LGIT provide robust efficacy for achieving ≥50% responder status with significantly improved palatability. LGIT is associated with the most favorable safety profile and highest patient compliance, particularly among adolescents, due to its less restrictive carbohydrate limits and lower incidence of serious gastrointestinal or metabolic adverse events. Recent advancements in precision medicine highlight the critical roles of genetic etiology, such as variants in SLC2A1 or SCN1A, and gut microbiome composition in predicting individual response to these therapies. With a favorable long-term safety profile when appropriately monitored, these metabolic protocols offer a vital non-pharmacological cornerstone for improving the quality of life for children and their caregivers. Further work is necessary to integrate digital health monitoring and personalized microbiome-targeted strategies to optimize dietary maintenance and therapeutic outcomes.

References

Ansari, A., et al. (2023). Dietary strategies for the management of epilepsy. Journal of Clinical Nutrition.

Barañano, K. W., & Hartman, A. L. (2010). The ketogenic diet: Uses in epilepsy and other neurologic illnesses. Current Treatment Options in Neurology, 12(2), 68–79. https://doi.org/10.1007/s11940-009-0060-2

Bartoszewicz, Z., et al. (2025). Impact of ketogenic diet therapy on nutritional status and growth in children. Child Neurology — Neurologia Dziecięca, 63(35).

Beniczky, S., et al. (2025). Updated classification of epileptic seizures (2025): Position paper of the International League Against Epilepsy. Epilepsia. https://doi.org/10.1111/epi.18338

Borrego-Ruiz, A., & Borrego, J. J. (2025). Therapeutic effects of ketogenic diets on physiological and mental health. Exploration of Foods and Foodomics, 3, 101079. https://doi.org/10.37349/eff.2025.101079

Chen, Y., et al. (2021). Microbiome-brain axis in seizure disorders. Frontiers in Neurology.

Deshpande, V. P., et al. (2023). Study of classic ketogenic diet vs. modified Atkins diet in treatment of refractory epilepsy in children. Journal of Childhood and Development Disorders, 9(4), 79.

Devi, N., Madaan, P., Kandoth, N., et al. (2023). Efficacy and safety of dietary therapies for childhood drug-resistant epilepsy: A systematic review and network meta-analysis. JAMA Pediatrics. https://doi.org/10.1001/jamapediatrics.2022.5648

El-Sharkawy, M., et al. (2024). Alteration of gut microbiota by ketogenic diet as an alternative therapeutic target for drug-resistant epilepsy. Microorganisms, 12(11), 2539. https://doi.org/10.3390/microorganisms13112539

Guery, D., & Rheims, S. (2021). Clinical management of drug resistant epilepsy: A review on current strategies. Neuropsychiatric Disease and Treatment, 17, 2229–2242. https://doi.org/10.2147/NDT.S256699

International League Against Epilepsy. (2009). Definition of drug resistant epilepsy 2009. Epilepsia, 51(6), 1069–1077.

Kim, H. D. (2018). The efficacy of ketogenic diet for specific genetic mutation in developmental and epileptic encephalopathy. Frontiers in Neurology, 9, 530. https://doi.org/10.3389/fneur.2018.00530

Kim, H. D. (2022). Updates on the ketogenic diet therapy for pediatric epilepsy. Biomedical Journal, 45(1), 19–26. https://doi.org/10.1016/j.bj.2021.11.003

Kim, J. A., Surn, J. I., van Kuijk, S. M. J., et al. (2016). Efficacy and tolerability of the ketogenic diet according to lipid:nonlipid ratios. Epilepsia, 57(1), 51–58. https://doi.org/10.1111/epi.13256

Kowalcze, K., et al. (2025). Modulation of gut microbiome and metabolome as potential mechanisms of ketogenic diet effect. Nutrients, 18(1), 31. https://doi.org/10.3390/nu18010031

Liu, J., E, R. H., Zhang, J. Q., & Wang, D. P. (2025). Impact of a high-fat, low-carbohydrate ketogenic diet on seizure frequency in children with drug-resistant epilepsy: A systematic review and meta-analysis. Frontiers in Nutrition, 12, 1634041. https://doi.org/10.3389/fnut.2025.1634041

Martin, K., et al. (2016). Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database of Systematic Reviews, 2016(2), CD001903. https://doi.org/10.1002/14651858.CD001903.pub3

Mendonça, C. N., et al. (2024). Quality of life of caregivers and drug-resistant epilepsy children treated with a ketogenic diet. Revista de Nutrição, 37, e230026. https://doi.org/10.1590/1678-9865202437e230026

Mulyan, A., Kaushik, J. S., & Dabla, S. (2024). Sequential treatment with modified Atkins diet and low glycemic index treatment for drug-resistant epilepsy in children. Neuropediatrics. https://doi.org/10.1055/s-0044-1787744

Neal, E. G., et al. (2008). The ketogenic diet for the treatment of childhood epilepsy: A randomised controlled trial. Lancet Neurology, 7(6), 500–506. https://doi.org/10.1016/S1474-4422(08)70092-9

Olson, C. A., Vuong, H. E., Yano, J. M., et al. (2018). The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell, 173(7), 1728–1741. https://doi.org/10.1016/j.cell.2018.04.027

Osipov, B., et al. (2026). Ketogenic diet causes bone loss in growing and adult mice. Bone, 207, 117854. https://doi.org/10.1016/j.bone.2026.117854

Panda, P. K., Chakrabarty, B., Jauhari, P., et al. (2024). Efficacy of daily versus intermittent low glycemic index therapy diet in children with drug-resistant epilepsy: A randomized controlled trial. Epilepsy Research, 201, 107322. https://doi.org/10.1016/j.eplepsyres.2024.107322

Peterson, L., et al. (2025). A two-year retrospective study on the impact of ketogenic diet therapy on growth in children. Child Neurology — Neurologia Dziecięca, 63(35).

Phoenix Children’s Medical Connection. (2021). Transforming toast with tech: Modernizing ketogenic therapy. https://www.phoenixchildrensmedconnection.org/news/transforming-toast-with-tech-modernizing-ketogenic-therapy

Phoenix Children’s Hospital. (2021). Our Journey™ with Ketogenic Diet Therapy application.

Rezaei, S., et al. (2025). Modified Atkins diet versus ketogenic diet in children with drug-resistant epilepsy. Clinical Nutrition ESPEN, 66, 465–473.

Rohani, M., et al. (2025). Low glycemic index treatment in pediatric drug-resistant epilepsy: A systematic review and meta-analysis. AES Abstract.

Rubio, C., Lopez-Landa, A., Romo-Parra, H., et al. (2025). Impact of the ketogenic diet on neurological diseases: A review. Life, 15(1), 71. https://doi.org/10.3390/life15010071

Schoeler, N. E., et al. (2025). Classical and modified ketogenic diets for children and young people with drug-resistant epilepsy. Journal of Human Nutrition and Dietetics, 38(5), e70129. https://doi.org/10.1111/jhn.70129

Sharaf, M. S., Abdelhamed, M. H., Salah, M., et al. (2025). Comparative efficacy of the classical ketogenic diet and modified Atkins diet in children. Nutrients, 17(6), 979. https://doi.org/10.3390/nu17060979

Sharawat, I. K., Panda, P., Dawman, L., Gupta, D., & Panda, P. K. (2025). Modified Atkins Diet versus low glycemic index treatment in children with drug-resistant epilepsy: A systematic review and meta-analysis. Seizure, 131, 471–479. https://doi.org/10.1016/j.seizure.2024.12.001

Sjölin, K., Sjölin, M., Arvidsson, J., et al. (2025). Genetic aetiologies in relation to response to the ketogenic diet in 226 children with epilepsy. Brain Communications, 7(2). https://doi.org/10.1093/braincomms/fcaf134

Sondhi, V., Agarwala, A., Pandey, R. M., et al. (2020). Efficacy of ketogenic diet, modified Atkins diet, and low glycemic index therapy diet among children with drug-resistant epilepsy: A randomized clinical trial. JAMA Pediatrics, 174(10), 944–951. https://doi.org/10.1001/jamapediatrics.2020.2282

Spulber, S., et al. (2025). Long-term effects of ketogenic diet on linear growth. Pediatric Neurology.

Van Delft, R., et al. (2009). Blood beta-hydroxybutyrate correlates better with seizure reduction than do ketones in the urine. Seizure, 18(10), 661–665. https://doi.org/10.1016/j.seizure.2009.10.009

Wilder, R. M. (1921). The effects of ketonemia on the course of epilepsy. Mayo Clinic Proceedings, 2, 307–308.

Wiradarma, E., et al. (2025). Effectiveness of medium-chain triglyceride diet and low glycemic index therapy in drug-resistant childhood epilepsy. Universa Medicina, 44(2), 245–256.

Wirrell, E. C., et al. (2018). Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open, 3(2), 175–192. https://doi.org/10.1002/epi4.12225

Xie, Z., Wang, Y., Zhang, J., et al. (2024). Real-world outcomes of ketogenic diet therapy in children with drug-resistant epilepsy in a prospective cohort study. Frontiers in Neurology.